Moderna, Inc. vs Teradata Corporation Common Stock — how do they compare? Moderna, Inc. trades at $224.52 (market cap $86.33B), while Teradata Corporation Common Stock trades at $29.6 (market cap $2.83B). The key difference: Moderna, Inc. is far larger — about 30.5× Teradata Corporation Common Stock's market cap, and Moderna, Inc. is trading nearer its 52-week high, Teradata Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Teradata Corporation Common Stock for 0 Days on average.
| MRNA | TDC | |
|---|---|---|
Market Cap | $86.33B | $2.83B |
Volume | 13,361,426 | 1,343,944 |
Sector | Health | Technology |
52-Week High | $226.30 | $37.88 |
52-Week Low | $22.36 | $20.71 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $82.48B | $2.52B |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $226.30, up 5.88% with strong technical momentum as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative profitability margins (-142.58% net income margin) and declining revenue from pandemic peaks. Technical indicators show bullish momentum with price above key support levels, while analyst sentiment remains divided with a $115.70 consensus target well below current levels.
The outlook balances Nasdaq inclusion benefits against valuation concerns after a 500% 2026 rally. Investment opportunity lies in the cancer vaccine pipeline growth, while risks include sustained profitability challenges and high valuation multiples (P/S 38.5) that may not justify current price levels given declining revenue trends.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →Teradata Corporation develops a hybrid cloud analytics and data platform, including its Teradata Vantage and VantageCloud products, that helps enterprises manage and analyze data across cloud, on-premises, and hybrid environments. It serves industries including retail, financial services, healthcare, and manufacturing.
Read more on TDC →